Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00745173 | Study Evaluating Premarin and Bazedoxifene Potential Interaction | PHASE1 | COMPLETED | 30 | — | — | Sep 1, 2008 | Oct 1, 2008 | Feb 12, 2009 | 1 | United States |
| NCT00543634 | Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women | PHASE1 | COMPLETED | 30 | — | — | Oct 1, 2007 | Dec 1, 2007 | Jun 22, 2010 | 1 | United States |
| NCT00472927 | Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro) | PHASE1 | COMPLETED | - | — | — | May 1, 2007 | Aug 1, 2007 | Dec 6, 2007 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Premarin | DRUG | - |
| Premarin/MPA | DRUG | 0.625 mg/2.5 mg X4 |
| Provera 10 mg | DRUG | 2.5 mg of MPA, 4 tablets dissoved in water |
| Premarin/MPA 0.45 mg/1.5 mg | DRUG | - |
Inclusion Criteria: * For inclusion into the study, women must be healthy and postmenopausal (either naturally or surgically) between the ages of 35 and 70, inclusive. * Blood hormone levels must be consistent with a postmenopausal state (for specified subjects). * They can either be a non-smoker o...